Concert Pharmaceuticals (Concert Pharmaceuticals) EPS Growth Rate (Future 3Y To 5Y Estimate) : N/A (As of May. 07, 2024)

View and export this data going back to 2014. Start your Free Trial

What is Concert Pharmaceuticals EPS Growth Rate (Future 3Y To 5Y Estimate)?

EPS Growth Rate (Future 3Y To 5Y Estimate) is the average growth rate of earnings per share (EPS) estimates over a 3-year to 5-year period.

As of today, Concert Pharmaceuticals's EPS Growth Rate (Future 3Y To 5Y Estimate) is N/A.

Competitive Comparison of Concert Pharmaceuticals's EPS Growth Rate (Future 3Y To 5Y Estimate)

For the Biotechnology subindustry, Concert Pharmaceuticals's EPS Growth Rate (Future 3Y To 5Y Estimate), along with its competitors' market caps and EPS Growth Rate (Future 3Y To 5Y Estimate) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Concert Pharmaceuticals's EPS Growth Rate (Future 3Y To 5Y Estimate) Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Concert Pharmaceuticals's EPS Growth Rate (Future 3Y To 5Y Estimate) distribution charts can be found below:

* The bar in red indicates where Concert Pharmaceuticals's EPS Growth Rate (Future 3Y To 5Y Estimate) falls into.

Concert Pharmaceuticals (NAS:CNCE) EPS Growth Rate (Future 3Y To 5Y Estimate) Explanation

EPS Growth Rate (Future 3Y To 5Y Estimate) s the average growth rate of earnings per share (EPS) estimates over a 3-year to 5-year period.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average earnings per share (EPS) estimates growth rate.

Concert Pharmaceuticals EPS Growth Rate (Future 3Y To 5Y Estimate) Related Terms

Thank you for viewing the detailed overview of Concert Pharmaceuticals's EPS Growth Rate (Future 3Y To 5Y Estimate) provided by GuruFocus.com. Please click on the following links to see related term pages.

Concert Pharmaceuticals (Concert Pharmaceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Concert Pharmaceuticals Inc (NAS:CNCE) » Definitions » EPS Growth Rate (Future 3Y To 5Y Estimate)

Comparable Companies

Traded in Other Exchanges

N/A

Address

65 Hayden Avenue, Suite 3000N, Lexington, MA, USA, 02421

Website

https://www.concertpharma.com

Concert Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. The company aims to discover and develop small-molecule drugs by incorporating new elements into known molecules or by leveraging the currently approved drugs to be used for new treatments. The pipeline consists of small molecules designed for oral administration to cure cystic fibrosis, inflammation, narcolepsy, residual schizophrenia, major depressive disorder, and Alzheimer's agitation.

Executives

James V Cassella	officer: Chief Development Officer	2091 STIERLIN COURT, MOUNTAIN VIEW CA 94043
Marc A. Becker	officer: CFO, PFO	175 CROSSING BLVD., 4TH FLOOR, FRAMINGHAM MA 01702
Nancy Stuart	officer: Chief Operating Officer	99 HAYDEN AVENUE, SUITE 500, LEXINGTON MA 02421
Jeffrey A Munsie	officer: Chief Legal Officer	CONCERT PHARMACEUTICALS, INC., 65 HAYDEN AVENUE, SUITE 3000N, LEXINGTON MA 02421
Roger D Tung	director, officer: Chief Executive Officer	99 HAYDEN AVENUE, SUITE 500, LEXINGTON MA 02421
Peter Barton Hutt	director
Thomas G Auchincloss	director	C/O METABOLIX, INC., 21 ERIE STREET, CAMBRIDGE MA 02139
Richard Aldrich	director	1365 MAIN STREET, WALTHAM MA 02451
Heek Christi Van	director	4001 MIRANDA AVENUE, PALO ALTO CA 94304
Biotechnology Value Fund L P	other: See Explanation of Responses	44 MONTGOMERY STREET, 40TH FL, SAN FRANCISCO CA 94104
Jesper Hoeiland	director	C/O RADIUS HEALTH, INC., 950 WINTER STREET, WALTHAM MA 02451
Ronald W Barrett	director	C/O XENOPORT, INC., 3410 CENTRAL EXPRESSWAY, SANTA CLARA CA 95051
Wendall Wierenga	director	12790 EL CAMINO REAL, C/O NEUROCRINE BIOSCIENCES, SAN DIEGO CA 92130
Wilfred E Jaeger	director	C/O THREE ARCH PARTNERS, 3200 ALPINE RD, PORTOLA VALLEY CA 94028
Meghan Fitzgerald	director	C/O VION PHARMACEUTICALS, INC., 4 SCIENCE PARK, NEW HAVEN CT 06511